Plus Therapeutics (PSTV) Operating Margin (2011 - 2026)
Plus Therapeutics (PSTV) reported Operating Margin of 692.51% for Q1 2026, down 35861.0% year-over-year from N/an in Q1 2025, and down 64.87% quarter-over-quarter from 420.04% in Q4 2025.
Plus Therapeutics (PSTV) Operating Margin (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 14 years of Operating Margin data on file, last reported at 692.51% in Q1 2026.
- Operating Margin for Q1 2026 came in at 692.51%, down 35861.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 364.36% (down 7753.0% YoY), and the FY2025 annual result was 293.46%, down 4114.0% from the prior year.
- Operating Margin slipped to 692.51% in Q1 2026 per PSTV's latest filing, from 420.04% in the prior quarter.
- Over five years, Operating Margin peaked at 73.89% in Q3 2023 and troughed at 6978.08% in Q3 2022.
- A 5-year average of 1043.92% and a median of 293.83% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2023 and 2026: Operating Margin surged 690420 bps in 2023, then plunged 35861 bps in 2026.
- A 5-year view of Operating Margin shows it stood at 4387.4% in 2022, then surged by 93 bps to 293.83% in 2023, then advanced by 6 bps to 276.2% in 2024, then plunged by 52 bps to 420.04% in 2025, then plunged by 65 bps to 692.51% in 2026.
- Business Quant data shows PSTV's Operating Margin at 692.51% in Q1 2026, 420.04% in Q4 2025, and 320.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Plus Therapeutics | 37.48 Mn | 22.37 Mn | - | -692.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -692.51% |
| Dec 31, 2025 | -420.04% |
| Sep 30, 2025 | -320.83% |
| Jun 30, 2025 | -110.65% |
| Mar 31, 2025 | -333.90% |
| Dec 31, 2024 | -276.20% |
| Sep 30, 2024 | -260.92% |
| Jun 30, 2024 | -289.05% |
| Mar 31, 2024 | -196.72% |
| Dec 31, 2023 | -293.83% |
| Sep 30, 2023 | -73.89% |
| Jun 30, 2023 | -80.37% |
| Mar 31, 2023 | -944.40% |
| Dec 31, 2022 | -4,387.40% |
| Sep 30, 2022 | -6,978.08% |
| Mar 31, 2019 | -308.11% |
| Dec 31, 2018 | -134.32% |
| Sep 30, 2018 | -259.56% |
| Jun 30, 2018 | -279.70% |
| Mar 31, 2018 | -595.35% |